These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 19611406)

  • 21. SOT/EUROTOX debate: biomarkers from blood and urine will replace traditional histopathological evaluation to determine adverse responses.
    Boekelheide K; Schuppe-Koistinen I
    Toxicol Sci; 2012 Oct; 129(2):249-55. PubMed ID: 22987450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity.
    Gao J; Ann Garulacan L; Storm SM; Hefta SA; Opiteck GJ; Lin JH; Moulin F; Dambach DM
    Toxicol In Vitro; 2004 Aug; 18(4):533-41. PubMed ID: 15130611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro assays and biomarkers for drug-induced phospholipidosis.
    Monteith DK; Morgan RE; Halstead B
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):687-96. PubMed ID: 17014389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers in translation; past, present and future.
    Lock EA; Bonventre JV
    Toxicology; 2008 Mar; 245(3):163-6. PubMed ID: 18272278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A strategy for risk management of drug-induced phospholipidosis.
    Chatman LA; Morton D; Johnson TO; Anway SD
    Toxicol Pathol; 2009 Dec; 37(7):997-1005. PubMed ID: 20008549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical perspective of urinary biomarkers for the detection of nephrotoxicity: what we know and what we need to know.
    Fuchs TC; Hewitt P
    Biomark Med; 2011 Dec; 5(6):763-79. PubMed ID: 22103611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Impedance matching' of data sets in biomarker research.
    Colatsky TJ
    Curr Opin Investig Drugs; 2010 Mar; 11(3):262-4. PubMed ID: 20178038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity.
    O'Callaghan JP; Sriram K
    Expert Opin Drug Saf; 2005 May; 4(3):433-42. PubMed ID: 15934851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic and genetic biomarkers of toxicity.
    Mendrick DL
    Toxicology; 2008 Mar; 245(3):175-81. PubMed ID: 18206287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Biological markers: utilization in drug development and approval].
    Gueyffier F; Dib M; Boissel JP
    Therapie; 2001; 56(4):355-61. PubMed ID: 11677852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients.
    Millán O; Urtasun N; Brunet M
    Transplant Rev (Orlando); 2009 Apr; 23(2):120-8. PubMed ID: 19298943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety evaluation to support First-In-Man investigations II: toxicology studies.
    Baldrick P
    Regul Toxicol Pharmacol; 2008 Jul; 51(2):237-43. PubMed ID: 18501490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do preclinical testing strategies help predict human hepatotoxic potentials?
    Peters TS
    Toxicol Pathol; 2005; 33(1):146-54. PubMed ID: 15805066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI for development of disease-modifying osteoarthritis drugs.
    Burstein D
    NMR Biomed; 2006 Oct; 19(6):669-80. PubMed ID: 16986116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accurate prediction of human drug toxicity: a major challenge in drug development.
    Li AP
    Chem Biol Interact; 2004 Nov; 150(1):3-7. PubMed ID: 15522257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies.
    Dixit R; Boelsterli UA
    Drug Discov Today; 2007 Apr; 12(7-8):336-42. PubMed ID: 17395094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
    Cavagnaro J; Silva Lima B
    Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protocol design for lymphokine testing in clinical studies of human cancer.
    Lotze MT; Rosenberg SA
    Lymphokine Res; 1986; 5 Suppl 1():S177-81. PubMed ID: 3784611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.